Table 2.
Comparison of patients and transplant characteristics according to pre-HSCT IL6 levels.
|
Pre-HSCT IL6
<2.5 pg/mL (n = 111) |
Pre-HSCT IL6
≥2.5 pg/mL (n = 55) |
p | |
|---|---|---|---|
| Patient age y, median (range) | 48 (15-76) | 50 (22-77) | 0.17 |
| Patient sex, male | 66 | 39 | 0.17 |
| HCT-CI, median (range) | 2 (0–7) | 3 (0–7) | 0.02 |
| Type of diagnosis, n | 0.53 | ||
| Acute leukemia | 69 | 35 | |
| MDS or MPN | 22 | 7 | |
| Lymphoma or MM | 19 | 12 | |
| other | 1 | 1 | |
| DRI at HSCT, n | <0.01 | ||
| Low or intermediate | 60 | 14 | |
| High | 45 | 29 | |
| Very high | 6 | 12 | |
| Conditioning, n | 0.49 | ||
| RIC | 17 | 6 | |
| MAC | 94 | 49 | |
| Type of donor, n | 0.19 | ||
| MRD | 26 | 10 | |
| MUD | 31 | 10 | |
| MMRD | 54 | 35 | |
| Stem cell source, n | 0.78 | ||
| PBSC | 100 | 51 | |
| BM | 11 | 4 | |
| H/D CMV status, n | 0.94 | ||
| Neg/neg | 8 | 3 | |
| Neg/pos | 5 | 3 | |
| Pos/neg | 23 | 10 | |
| Pos/pos | 75 | 39 |
HSCT, Hematopoietic stem cell transplantation; HCT-CI, hematopoietic cell transplantation-comorbidity index; MDS, myelodysplastic syndromes; MPN, myeloproliferative neoplasms; MM, multiple myeloma; DRI, Disease Risk Index; MAC, myeloablativeconditioning; RIC, reduced-intensity conditioning; MMRD, mismatched related donor; MRD, matched related donor; MUD, matched unrelated donor; PBSC, peripheral blood stem cells; BM, bone marrow; H/D, host/donor; CMV, cytomegalovirus.